(AOF) – Valneva, a company specializing in vaccines, announced new positive results in adolescents for the pivotal Phase 3 study of its single-dose vaccine against the chikungunya virus. Following an initial analysis of study VLA1553-321 performed on day 29 post-vaccination, the most recent analysis assessed safety and immunogenicity six months (day 180) post-vaccination with a single dose of the vaccine.
The day 180 results confirmed the previously announced positive initial immunogenicity and safety data in adolescents, and are expected to allow the company to submit an application for expansion of use in adolescents aged 13 to 17 years. .
These results should also allow the approval of the vaccine in Brazil, which would then constitute the first marketing authorization for use in an endemic population.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
